Epidemiology of systemic sclerosis in Quebec, Canada: a population-based study
- PMID: 38962065
- PMCID: PMC11220520
- DOI: 10.1016/j.lana.2024.100790
Epidemiology of systemic sclerosis in Quebec, Canada: a population-based study
Abstract
Background: Systemic sclerosis (SSc) is a systemic life-threatening autoimmune rheumatic disease. We aimed to assess the incidence, prevalence, mortality and spatiotemporal trends of SSc in Quebec, Canada with stratification by sex and age.
Methods: SSc cases were identified from Quebec populational databases from 1989 to 2019. Negative Binomial (NB) Generalized Linear Models were used for age-standardized incidence rates (ASIR) analyses and NB random walk for prevalence and mortality. A Poisson Besag-York-Mollié regression model was used for spatial analysis.
Findings: 8180 incident SSc cases were identified between 1996 and 2019 with an average age of 57.3 ± 16.3 years. The overall ASIR was 4.14/100,000 person-years (95%, Confidence Interval (CI) 4.05-4.24) with a 4:1 female predominance. ASIR increased steadily over time with an Average Annual Percent Change (AAPC) of 3.94% (95% CI 3.49-4.38). While the highest incidence rates were in those aged 60-79 years old among females and >80 years old among males, the highest AAPC (∼10%) was seen in children. Standarized incidence ratios varied geographically between 0.52 to 1.64. The average prevalence was 28.96/100,000 persons (95% CI 28.72-29.20). The Standardized Mortality Ratio (SMR) decreased from 4.18 (95% CI 3.64-4.76) in 1996 to 2.69 (95% CI 2.42-2.98) in 2019. Females had a greater SMR until 2007 and males thereafter. The highest SMR was in children and young adults [31.2 (95% CI 8.39-79.82) in the 0-19-year age group].
Interpretation: We showed an increasing trend in SSc incidence and prevalence and a decline in SMR over a 25-year period in Quebec. An uneven geographic distribution of SSc incidence was demonstrated.
Funding: National Scleroderma Foundation, Canadian Dermatology Foundation/Canadian Institutes of Health Research.
Keywords: Epidemiology; Incidence; Mortality; Populational; Prevalence; Systemic sclerosis.
© 2024 The Authors.
Conflict of interest statement
The authors have no declaration of interest to disclose.
Figures







Similar articles
-
Incidence, prevalence, and mortality of localized scleroderma in Quebec, Canada: a population-based study.Lancet Reg Health Am. 2025 Mar 19;44:101044. doi: 10.1016/j.lana.2025.101044. eCollection 2025 Apr. Lancet Reg Health Am. 2025. PMID: 40206390 Free PMC article.
-
Epidemiology and mortality of systemic sclerosis: a nationwide population study in Taiwan.Scand J Rheumatol. 2011;40(5):373-8. doi: 10.3109/03009742.2011.553736. Epub 2011 Mar 9. Scand J Rheumatol. 2011. PMID: 21388247
-
Global, regional, and national burden of thalassemia, 1990-2021: a systematic analysis for the global burden of disease study 2021.EClinicalMedicine. 2024 May 6;72:102619. doi: 10.1016/j.eclinm.2024.102619. eCollection 2024 Jun. EClinicalMedicine. 2024. PMID: 38745964 Free PMC article.
-
Age-standardized incidence, prevalence, and mortality rates of autoimmune diseases in women of childbearing age from 1990 to 2019.Autoimmun Rev. 2023 Nov;22(11):103450. doi: 10.1016/j.autrev.2023.103450. Epub 2023 Sep 21. Autoimmun Rev. 2023. PMID: 37741529 Review.
-
Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature.Arthritis Res Ther. 2019 Apr 3;21(1):86. doi: 10.1186/s13075-019-1867-1. Arthritis Res Ther. 2019. PMID: 30944015 Free PMC article.
Cited by
-
Incidence, prevalence, and mortality of localized scleroderma in Quebec, Canada: a population-based study.Lancet Reg Health Am. 2025 Mar 19;44:101044. doi: 10.1016/j.lana.2025.101044. eCollection 2025 Apr. Lancet Reg Health Am. 2025. PMID: 40206390 Free PMC article.
References
-
- van den Hoogen F., Khanna D., Fransen J., et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72:1747–1755. - PubMed
-
- Avouac J., Fransen J., Walker U.A., et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a delphi consensus study from EULAR scleroderma trials and research group. Ann Rheum Dis. 2011;70:476–481. - PubMed
-
- Bellando-Randone S., Del Galdo F., Lepri G., et al. Progression of patients with Raynaud’s phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for very early diagnosis of systemic sclerosis (VEDOSS) Lancet Rheumatol. 2021;3:e834–e843. - PubMed
-
- Zhong L., Pope M., Shen Y., et al. Prevalence and incidence of systemic sclerosis: a systematic review and meta-analysis. Int J Rheum Dis. 2019;22:2096–2107. - PubMed
LinkOut - more resources
Full Text Sources